Plasfer

Plasfer is an early-stage biotech company developing a novel platform that engineers platelets into therapeutic agents. Leveraging platelets' natural properties—such as their longevity, safety profile, and ability to target sites of injury and inflammation—the company aims to create off-the-shelf, cell-based drugs for a range of serious conditions. As a private, pre-clinical stage company, Plasfer is likely focused on platform validation, proof-of-concept studies, and securing non-dilutive and venture funding to advance its research. The company represents a unique approach in the cell and gene therapy sector by utilizing anucleate blood cells as delivery vehicles.

Platelet Transfer Technology: A platform engineering platelets to serve as targeted delivery vehicles for therapeutic payloads, leveraging their natural longevity, safety profile, and tropism for sites of injury and inflammation.

Plasfer operates in the competitive cell & gene therapy and drug delivery sectors. Direct competitors may include other companies engineering blood cells (e.g., red blood cells) or extracellular vesicles for delivery. It also competes broadly with other targeted delivery platforms (lipid nanoparticles, antibody-drug conjugates) and off-the-shelf allogeneic cell therapy approaches.